Arvinas Publishes Corporate Presentation on PROTAC Protein Degraders for Cancer and Neurodegenerative Diseases

Reuters

Yesterday

Arvinas Publishes Corporate Presentation on PROTAC Protein Degraders for Cancer and Neurodegenerative Diseases

Arvinas Inc. released a corporate presentation outlining updates on its PROTAC protein degrader pipeline in oncology and neurology. The company highlighted vepdegestrant (ARV-471), an oral estrogen receptor degrader for metastatic breast cancer, noting a submitted U.S. FDA new drug application with a PDUFA date of June 5, 2026, and ongoing combination trials. The presentation also covered luxdegalutamide (ARV-766/JSB462), an androgen receptor degrader licensed to Novartis and being evaluated in Phase 2 combination trials in metastatic prostate cancer settings, and provided pipeline updates including ARV-102 (LRRK2) in Phase 1 for Parkinson’s disease, ARV-027 for spinal bulbar muscular atrophy, ARV-806 (KRAS G12D) in Phase 1 solid tumors, ARV-393 (BCL6) in Phase 1 for non-Hodgkin lymphoma, and ARV-6723 (HPK1) in preclinical development for advanced solid tumors. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2613055711"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613055711\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613055711?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613055711","market":"fut","top_or_hot":-1,"title":"Arvinas Publishes Corporate Presentation on PROTAC Protein Degraders for Cancer and Neurodegenerative Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arvinas Publishes Corporate Presentation on PROTAC Protein Degraders for Cancer and Neurodegenerative Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arvinas Inc. released a corporate presentation outlining updates on its PROTAC protein degrader pipeline in oncology and neurology. The company highlighted vepdegestrant (ARV-471), an oral estrogen receptor degrader for metastatic breast cancer, noting a submitted U.S. FDA new drug application with a PDUFA date of June 5, 2026, and ongoing combination trials. The presentation also covered luxdegalutamide (ARV-766/JSB462), an androgen receptor degrader licensed to Novartis and being evaluated in Phase 2 combination trials in metastatic prostate cancer settings, and provided pipeline updates including ARV-102 (LRRK2) in Phase 1 for Parkinson’s disease, ARV-027 for spinal bulbar muscular atrophy, ARV-806 (KRAS G12D) in Phase 1 solid tumors, ARV-393 (BCL6) in Phase 1 for non-Hodgkin lymphoma, and ARV-6723 (HPK1) in preclinical development for advanced solid tumors. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arvinas Publishes Corporate Presentation on PROTAC Protein Degraders for Cancer and Neurodegenerative Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArvinas Publishes Corporate Presentation on PROTAC Protein Degraders for Cancer and Neurodegenerative Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arvinas Publishes Corporate Presentation on PROTAC Protein Degraders for Cancer and Neurodegenerative Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arvinas Inc. released a corporate presentation outlining updates on its PROTAC protein degrader pipeline in oncology and neurology. The company highlighted vepdegestrant (ARV-471), an oral estrogen receptor degrader for metastatic breast cancer, noting a submitted U.S. FDA new drug application with a PDUFA date of June 5, 2026, and ongoing combination trials. The presentation also covered luxdegalutamide (ARV-766/JSB462), an androgen receptor degrader licensed to Novartis and being evaluated in Phase 2 combination trials in metastatic prostate cancer settings, and provided pipeline updates including ARV-102 (LRRK2) in Phase 1 for Parkinson’s disease, ARV-027 for spinal bulbar muscular atrophy, ARV-806 (KRAS G12D) in Phase 1 solid tumors, ARV-393 (BCL6) in Phase 1 for non-Hodgkin lymphoma, and ARV-6723 (HPK1) in preclinical development for advanced solid tumors. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL7ChgT7:1","article_id":"2613055711","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613055711","pubTimestamp":1771938560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arvinas Inc. released a corporate presentation outlining updates on its PROTAC protein degrader pipeline in oncology and neurology. The company highlighted vepdegestrant , an oral estrogen receptor degrader for metastatic breast cancer, noting a submitted U.S. FDA new drug application with a PDUFA date of June 5, 2026, and ongoing combination trials. The presentation also covered luxdegalutamide , an androgen receptor degrader licensed to Novartis and being evaluated in Phase 2 combination trials in metastatic prostate cancer settings, and provided pipeline updates including ARV-102  in Phase 1 for Parkinson’s disease, ARV-027 for spinal bulbar muscular atrophy, ARV-806  in Phase 1 solid tumors, ARV-393  in Phase 1 for non-Hodgkin lymphoma, and ARV-6723  in preclinical development for advanced solid tumors. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT stri","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ARVN":"Arvinas Holding Company LLC"},"translate_title":"Arvinas发布关于治疗癌症和神经退行性疾病的PROTAC蛋白降解剂的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARVN":0.9},"content_text":"Arvinas Publishes Corporate Presentation on PROTAC Protein Degraders for Cancer and Neurodegenerative Diseases\n    \n\n        Arvinas Inc. released a corporate presentation outlining updates on its PROTAC protein degrader pipeline in oncology and neurology. The company highlighted vepdegestrant (ARV-471), an oral estrogen receptor degrader for metastatic breast cancer, noting a submitted U.S. FDA new drug application with a PDUFA date of June 5, 2026, and ongoing combination trials. The presentation also covered luxdegalutamide (ARV-766/JSB462), an androgen receptor degrader licensed to Novartis and being evaluated in Phase 2 combination trials in metastatic prostate cancer settings, and provided pipeline updates including ARV-102 (LRRK2) in Phase 1 for Parkinson’s disease, ARV-027 for spinal bulbar muscular atrophy, ARV-806 (KRAS G12D) in Phase 1 solid tumors, ARV-393 (BCL6) in Phase 1 for non-Hodgkin lymphoma, and ARV-6723 (HPK1) in preclinical development for advanced solid tumors. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}